A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) products

Current Medical Research and Opinion

Volumn 21, Issue 6, 2005, Pages 877-883

  Cowden, David I ^a   Fisher, G E ^a   Weeks, R L ^a  

^a ZLB Behring LLC   (United States)

Author keywords

Alpha 1 antitrypsin; Alpha 1 proteinase inhibitor; Aralast; Emphysema; Prolastin; Zemaira

Indexed keywords

ALPHA 1 ANTITRYPSIN; LEUKOCYTE ELASTASE; ZEMAIRA;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANALYTIC METHOD; ANTIGENICITY; ARTICLE; CAPILLARY ZONE ELECTROPHORESIS; COMPARATIVE STUDY; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG IMPURITY; DRUG PURITY; EVALUATION; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNONEPHELOMETRY; ISOELECTRIC FOCUSING; LUNG EMPHYSEMA; NEPHELOMETRY; PILOT STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; WESTERN BLOTTING;

ALPHA 1-ANTITRYPSIN; BLOTTING, WESTERN; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS, CAPILLARY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; PILOT PROJECTS; PROTEIN ISOFORMS; UNITED STATES;

EID: 21244492343     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X46395     Document Type: Article

References (18)

1. American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003;168:818-900
2. 1-antitrypsin deficiency. Chest 2000;118(3):843-8
3. 1-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy. Chest 1989;95:196-208
4. World Health Organization, Human Genetics Programme. Alpha-1-antitrypsin deficiency. Report of a WHO meeting, Geneva, 18-20 March 1996
5. Laurell C-B, Eriksson S. The electrophoretic α-1-globulin pattern of serum in α-1 antitrypsin deficiency. Scand J Clin Lab Invest 1963;15:132-40
6. De Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002;122: 1818-29
7. Alpha-1 Foundation. A healthcare provider's guide to alpha-1 antitrypsin deficiency [online]. Available from http://www. alphaone.org/documents/pdf/ Alpha-1%20HCPG.pdf [accessed 23 March 2005]
8. US Food and Drug Administration. Summary basis of approval. Aralast™ [online]. Available from http://www.fda.gov/cber/sba/ alpha1p122302S.pdf [accessed 23 March 2005]
9. Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma α1-antitrypsin, Respitin. Chest 2002;122:66-74
10. US Food and Drug Administration. Product approval information. Zemaira® [online]. Available from http://www.fda.gov/cber/ approvltr/alphave070803L.htm [accessed 23 March 2005]
11. ZLB Behring Data on File
12. Abboud RT, Ford GT, Chapman KR. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome? Treat Respir Med 2005;4:1-8
13. Coan MH, Brockway WJ, Eguizabal H, Kreig T, Fournel M. Preparation and properties of alpha 1-proteinase inhibitor concentrate from human plasma. Vox Sang 1985;48:333-2
14. 1-proteinase inhibitor (human), full prescribing information, January 2003 [online]. Available from http://www. aralast.com/PDF/aralast_pi.pdf [accessed 23 March 2005]
15. 1-proteinase inhibitor (human), full prescribing information, March 2003. Available from http://www.univgraph. com/bayer/inserts/prolastin.pdf [accessed 23 March 2005]
16. 1-proteinase inhibitor (human), full prescribing information, December 2003 [online]. Available from http:// www.zemaira.com/zCommon/zemairaP1.pdf [accessed 23 March 2005]
17. Brantly M. Alpha 1-anti-trypsin genotypes and phenotypes. In: Crystal RG, editor. Lung biology in health and disease, vol. 88. Marcel Dekker, Inc; 1996. p. 47
18. 1-antitrypsin variants in plasma with the use of proteomic technology. Clin Chem 2001;47: 2012-22